Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 12/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23568284 | 0.91 | CYP2D6 (0.61) | CYP2D6ALDH1A1CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL24672759 | 0.90 | CYP2D6 (0.52) | CYP2D6ALDH1A1CYP3A4TSHRCYP2C9 | |
| SCHEMBL25654337 | 0.88 | CYP2D6 (0.52) | CYP2D6ALDH1A1CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL23471284 | 0.86 | PIK3CD (0.58) | L3MBTL1MEN1KMT2ATDP1PIK3CD | |
| SCHEMBL25728641 | 0.86 | CYP2D6 (0.50) | CYP2D6ALDH1A1CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL23560014 | 0.85 | CYP2D6 (0.61) | CYP2D6ALDH1A1CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL25728592 | 0.85 | CYP2D6 (0.50) | CYP2D6TSHRCYP2C9L3MBTL1MEN1 | |
| SCHEMBL23806494 | 0.84 | CYP2D6 (0.65) | CYP2D6ALDH1A1CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL25123000 | 0.83 | L3MBTL1 (0.45) | CYP2D6ALDH1A1CYP3A4L3MBTL1MEN1 | |
| SCHEMBL25924028 | 0.83 | L3MBTL1 (0.42) | CYP2D6ALDH1A1CYP3A4TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192586-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| WO-2022125804-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885ALDH1A1 2776/4885CYP3A4 2542/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885ALDH1A1 2776/4885CYP3A4 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.